Patents by Inventor Christophe Ginestier
Christophe Ginestier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10557850Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: GrantFiled: December 10, 2014Date of Patent: February 11, 2020Assignee: THE REGENTS OF UNIVERSITY OF MICHIGANInventors: Max S. Wicha, Christophe Ginestier
-
Patent number: 9606124Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: GrantFiled: December 10, 2014Date of Patent: March 28, 2017Assignee: The Regents of the University of MichiganInventors: Max S. Wicha, Christophe Ginestier
-
Publication number: 20160040251Abstract: The instant application provides biomarkers for the identification of chemosensitivity in patient having cancer, in a particular embodiment the invention provides MST for the identification of chemosensitivity in breast cancer patient, wherein a reduced expression of XIST in the breast cancer cells of the patient indicates that the breast cancer stem cells in the patient may be successfully treated with HDAC inhibitor.Type: ApplicationFiled: April 4, 2014Publication date: February 11, 2016Applicant: PHARMACYCLICS, LLCInventors: Daniel BIRNBAUM, Emmanuelle CHARAFE-JAUFFRET, Christophe GINESTIER, Marion SALVADOR
-
Publication number: 20160017439Abstract: An in vitro method for diagnosing a breast cancer from the luminal-B subtype in a female, includes the steps of analyzing a biological sample from the female by (i) determining the copies number of the ZNF703 gene, and/or (ii) determining the expression of the ZNF703 gene, wherein an increased copies number and/or an over-expression of the ZNF703 gene is indicative of a luminal B tumor; to a kit for diagnosing a breast cancer from the luminal-B subtype in a female including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a method as defined previously, for determining the copies number of the ZNF703 gene, and/or determining the expression of the ZNF703 gene; and to the use of such a kit.Type: ApplicationFiled: September 22, 2015Publication date: January 21, 2016Inventors: Daniel BIRNBAUM, Max CHAFFANET, Christophe GINESTIER, Jose ADELAIDE, Fabrice COULOMB
-
Publication number: 20150160227Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: ApplicationFiled: December 10, 2014Publication date: June 11, 2015Inventors: Max S. Wicha, Christophe Ginestier
-
Publication number: 20150094362Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Inventors: Max S. Wicha, Christophe Ginestier
-
Patent number: 8940301Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: GrantFiled: November 11, 2009Date of Patent: January 27, 2015Assignee: The Regents of The University of MichiganInventors: Max S. Wicha, Christophe Ginestier
-
Publication number: 20130295571Abstract: An in vitro method for diagnosing a breast cancer from the luminal-B subtype in a female, includes the steps of analyzing a biological sample from the female by (i) determining the copies number of the ZNF703 gene, and/or (ii) determining the expression of the ZNF703 gene, wherein an increased copies number and/or an over-expression of the ZNF703 gene is indicative of a luminal B tumor; to a kit for diagnosing a breast cancer from the luminal-B subtype in a female including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a method as defined previously, for determining the copies number of the ZNF703 gene, and/or determining the expression of the ZNF703 gene; and to the use of such a kit.Type: ApplicationFiled: October 28, 2011Publication date: November 7, 2013Applicant: INSTITUT NATIONAL DE LA SANTEE ET DE LA RECHERCHE MEDICALE ( INSERM)Inventors: Daniel Birnbaum, Max Chaffanet, Christophe Ginestier, Jose Adelaide, Fabrice Sircoulomb
-
Patent number: 8435746Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.Type: GrantFiled: July 6, 2010Date of Patent: May 7, 2013Assignee: The Regents of the University of MichiganInventors: Max S. Wicha, Gabriela Dontu, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Suling Liu
-
Publication number: 20100291581Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.Type: ApplicationFiled: July 6, 2010Publication date: November 18, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Max S. Wicha, Gabriela Dontu, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Suling Liu
-
Publication number: 20100136031Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: ApplicationFiled: November 11, 2009Publication date: June 3, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Max S. Wicha, Christophe Ginestier
-
Publication number: 20090092983Abstract: A method for analyzing differential gene expression associated with breast tumor is based on the analysis of the over-expression or under-expression of polynucleotide sequences in a biological sample. The analysis includes the detection of the over-expression of at least one polynucleotide sequence(s), subsequence(s) or complement(s) thereof selected from predefined polynucleotide sequence sets.Type: ApplicationFiled: September 17, 2008Publication date: April 9, 2009Inventors: Daniel Birnbaum, Francois Bertucci, Jocelyne Jacquemier, Stephane Debono, Nathalie Borie, Christophe Ginestier
-
Publication number: 20080187938Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH1, useful for the diagnosis, characterization, and treatment of solid tumor stem cells.Type: ApplicationFiled: September 24, 2007Publication date: August 7, 2008Applicant: The Regents of the University of MichiganInventors: Max S. Wicha, Gabriela Dontu, Christophe Ginestier, Emmanuelle Charafe-Jauffret, Suling Liu
-
Publication number: 20050089899Abstract: The present invention relates to a method for analyzing differential gene expression associated with breast tumor, based on the analysis of the over-expression or under-expression of polynucleotide sequences in a biological sample. The analysis comprises the detection of the over-expression of at least one polynucleotide sequence(s), subsequence(s) or complement(s) thereof selected from predefined polynucleotide sequence sets.Type: ApplicationFiled: August 27, 2004Publication date: April 28, 2005Inventors: Daniel Birnbaum, Francois Bertucci, Jocelyne Jacquemier, Stephane Debono, Nathalie Borie, Christophe Ginestier